Tatiana Guerrero-Hernandez
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 20, 2026
Derivation and External Validation of Objective Performance Status Among Patients With Metastatic Cancer.
Journal: JCO oncology practice
Published: July 25, 2025
GITR Antibodies in Cancer: Not Ready for Prime Time.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 02, 2022
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.
Journal: Nature communications
Published: January 14, 2022
Increased vulnerability of clinical research units during the COVID-19 crisis and their protection.
Journal: Cancer
Published: April 20, 2020
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 06, 2019
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Journal: Drugs of today (Barcelona, Spain : 1998)
Published: August 29, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026